LONDON, June 8, 2026, 13:04 BST
GSK plc was down nearly 1% in early afternoon trading Monday in London, trailing the UK blue-chips. A new liver-fibrosis research deal didn’t move investors off concerns about GSK’s pipeline. The stock traded at about 1,919.5 pence, off 0.95%. The main UK share index edged up 0.11%.
The story is in focus now because GSK’s value depends more on whether new CEO Luke Miels can show the company has enough late-stage drugs to make up for losses from older products and meet long-term sales targets, not on one small research deal. Reuters said in April that Miels is under investor pressure over GSK’s 2031 revenue target and the 2028 patent loss for its HIV drug dolutegravir. James Eugene, research analyst at Verso Investment Management, told Reuters then that investors had “quality concerns” about that first-quarter earnings beat. Reuters
GSK has signed a research collaboration and option deal with Engitix to hunt for new targets for liver fibrosis regression, Engitix said Monday. Liver fibrosis is scarring that may cause cirrhosis, liver failure or cancer. Under the agreement, Engitix could get up to £44.5 million in upfront and near-term payments, plus up to £118 million for each target in milestones, and low-single-digit royalties if any drugs reach the market.
Giuseppe Mazza, Engitix’s co-founder and CEO, called the collaboration “very significant”. Kaivan Khavandi, a senior research executive at GSK, said the drugmaker was “excited to collaborate” and Engitix’s human-biology platform would help with fibrosis-targeted medicines. Businessinsider
Healthcare names didn’t face much pushback in the market today. The FTSE 100 pared its earlier losses as oil prices slipped. European shares found footing after Middle East jitters and a tech rout hit Asia and Wall Street.
The competition is heating up. Boehringer Ingelheim’s obesity drug, developed with Zealand Pharma, delivered reductions in visceral and liver fat, Reuters said this weekend. That pushes into metabolic-liver research, with some overlap in efforts to go past just weight loss.
GSK is pushing further into hepatology. In April, the company said its once-monthly MASH drug efimosfermin picked up U.S. FDA Breakthrough Therapy and EMA PRIME status — both are regulatory designations that aim to speed up review or add extra support for drugs aimed at serious illness. At the time, Khavandi said the drug could improve care by “directly targeting liver fibrosis.” GSK
GSK is also working to establish a liver business in China. In May, the company said it signed an exclusive deal with Sino Biopharmaceutical’s Chia Tai Tianqing arm for the China launch of bepirovirsen, which is GSK’s experimental drug for chronic hepatitis B. GSK puts the hepatitis B patient number in China at around 75 million. “The partnership aimed to reach more patients,” said Mike Crichton, president international at GSK.
GSK’s own collected consensus as of May 26 shows 2026 turnover at £33.67 billion, with 2031 at £34.88 billion. That still trails the company’s target for more than £40 billion turnover by 2031. The consensus looks for specialty medicines to rise until 2029, then slow later on. Analyst estimates don’t leave much wiggle room.
The risk stands out. Monday’s Engitix deal is about early-stage research, not any new product. Most of the money depends on the projects hitting targets, successful trials, and regulators signing off. Other companies are also making moves. A broader market drop could push investors to stick with cash flow, dividends, and near-term sales instead of bets on science that could take years.
GSK’s next test is close. The company plans to report second-quarter results and talk about portfolio growth on July 28. Investors will want more concrete signs that small acquisitions, late-stage trials, and deals in China can help GSK bridge the gap to its 2031 target, which is above consensus.
